Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 (Oral Stable Form) | Cerebrolysin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg twice daily via oral capsule on empty stomach. | Research indicates 10-30 mL daily via intravenous infusion for neurological indications. 5-10 mL for cognitive optimization. |
| Timing | On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels. | Morning administration preferred for cognitive effects. IV infusion over 15-20 minutes. |
| Cycle Duration | 4-12 weeks. Oral form enables easier long-term use compared to injectable. | 10-20 day intensive cycles repeated every 3-6 months. Some protocols use ongoing 3x weekly maintenance. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.
Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.
On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.
4-12 weeks. Oral form enables easier long-term use compared to injectable.
Cerebrolysin is a porcine brain-derived peptide preparation containing a standardized mixture of low-molecular-weight neuropeptides (<10 kDa) and free amino acids obtained through enzymatic proteolysis. It exerts multimodal neurotrophic effects by simultaneously upregulating VEGF, BDNF, IGF-1, and NGF while downregulating TNF-alpha. Cerebrolysin increases furin protease concentration, which promotes pro-NGF to mature NGF conversion. It activates TrkB receptor signaling (BDNF/TrkB/CREB pathway), inhibits neuronal apoptosis, reduces microglial activation, and promotes neurogenesis.
Research indicates 10-30 mL daily via intravenous infusion for neurological indications. 5-10 mL for cognitive optimization.
Morning administration preferred for cognitive effects. IV infusion over 15-20 minutes.
10-20 day intensive cycles repeated every 3-6 months. Some protocols use ongoing 3x weekly maintenance.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →